4.6 Article

New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4

Journal

MOLECULES
Volume 27, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/molecules27051682

Keywords

multifunctional thiosemicarbazone; s-2 receptor ligands; pancreatic cancer primary cultures; chemoresistance; migration

Funding

  1. CCA Foundation
  2. KWF Dutch Cancer Society [19571]
  3. AIRC IG [24444, 21408]
  4. CRT Foundation [2021-0556]
  5. EU Social Fund (FSE)
  6. Canary Islands ACIISI [TESIS2020010055, EST2021010019]
  7. COST Action [CA17104 STRATAGEM]
  8. COST (European Cooperation in Science and Technology)

Ask authors/readers for more resources

A new sigma-2 receptor ligand FA4 was synthesized and evaluated for its anti-proliferative, pro-apoptotic, and anti-migratory activity on PDAC primary cell cultures. The results showed that FA4 effectively inhibited the aggressive and chemoresistant behavior of PDAC, with significant antiproliferative and antimigratory effects.
A new sigma-2 (sigma 2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relevant antiproliferative activity with half maximal inhibitory concentration (IC50) values ranging from 0.701 to 0.825 mu M. The cytotoxic activity was associated with induction of apoptosis, resulting in apoptotic indexes higher than those observed after exposure to a clinically relevant concentration of the gemcitabine, the first-line drug used against PDAC. Interestingly, FA4 was also able to significantly inhibit the migration rate of both PDAC-1 and PDAC-2 cells in the scratch wound-healing assay. In conclusion, our results support further studies to improve the library of thiosemicarbazones targeting the sigma-2 receptor for a deeper understanding of the relationship between the biological activity of these compounds and the development of more efficient anticancer compounds against PDAC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available